Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review
Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/12/2244 |
| _version_ | 1797380364243566592 |
|---|---|
| author | Krasimir Kraev Mariela Gencheva Geneva-Popova Bozhidar Krasimirov Hristov Petar Angelov Uchikov Stanislava Dimitrova Belova-Popova Maria Ilieva Kraeva Yordanka Mincheva Basheva-Kraeva Nina Staneva Stoyanova Vesela Todorova Mitkova-Hristova Maria Stoyanova Koleva-Ivanova Daniela Ivova Taneva Atanas Slavchev Ivanov |
| author_facet | Krasimir Kraev Mariela Gencheva Geneva-Popova Bozhidar Krasimirov Hristov Petar Angelov Uchikov Stanislava Dimitrova Belova-Popova Maria Ilieva Kraeva Yordanka Mincheva Basheva-Kraeva Nina Staneva Stoyanova Vesela Todorova Mitkova-Hristova Maria Stoyanova Koleva-Ivanova Daniela Ivova Taneva Atanas Slavchev Ivanov |
| author_sort | Krasimir Kraev |
| collection | DOAJ |
| description | Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical scrutiny. This comprehensive literature review embarks on an exploration of the multifaceted landscape of JAK inhibitors, providing insights into their safety profiles across diverse immune-mediated diseases. The introduction highlights the transformative influence of JAK inhibitors in the treatment of immune-mediated diseases. Historically, the therapeutic arsenal for these conditions included corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics. The advent of JAK inhibitors has revolutionized this landscape, although concerns about their safety persist. This review strives to comprehensively evaluate their safety, amalgamating knowledge from multiple studies and trials. The subsequent sections delve into the safety of specific JAK inhibitors in the context of rheumatoid arthritis, inflammatory bowel diseases, and dermatologic conditions and their associations with venous thromboembolism. The evolving understanding of TE risk, particularly the intricate relationship between these agents and immune-mediated diseases, is meticulously unravelled. The concluding remarks underscore the dynamic nature of TE risk assessment with regard to immune-mediated diseases involving JAK inhibitors. It underscores that risk assessment is multifactorial, influenced not only by the choice of JAK inhibitor but also by the nuances of the underlying immune-mediated disease and the unique patient characteristics. This review offers a holistic perspective on TE risks associated with JAK inhibitors and contributes to the ongoing dialogue regarding their safety in the realm of immune-mediated diseases. |
| first_indexed | 2024-03-08T20:36:13Z |
| format | Article |
| id | doaj.art-cc6c5ba9076b4cbda08fa5c414235ffb |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-08T20:36:13Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-cc6c5ba9076b4cbda08fa5c414235ffb2023-12-22T14:21:04ZengMDPI AGLife2075-17292023-11-011312224410.3390/life13122244Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive ReviewKrasimir Kraev0Mariela Gencheva Geneva-Popova1Bozhidar Krasimirov Hristov2Petar Angelov Uchikov3Stanislava Dimitrova Belova-Popova4Maria Ilieva Kraeva5Yordanka Mincheva Basheva-Kraeva6Nina Staneva Stoyanova7Vesela Todorova Mitkova-Hristova8Maria Stoyanova Koleva-Ivanova9Daniela Ivova Taneva10Atanas Slavchev Ivanov11Department of Propedeutics of Internal Diseases, Medical Faculty, Medical University of Plovdiv, 4000 Plovdiv, BulgariaDepartment of Propedeutics of Internal Diseases, Medical Faculty, Medical University of Plovdiv, 4000 Plovdiv, BulgariaSecond Department of Internal Diseases, Medical Faculty, Medical University of Plovdiv, 6000 Plovdiv, BulgariaDepartment of Special Surgery, Medical Faculty, Medical University of Plovdiv, 6000 Plovdiv, BulgariaDepartment of Propedeutics of Internal Diseases, Medical Faculty, Medical University of Plovdiv, 4000 Plovdiv, BulgariaDepartment of Otorhynolaryngology, Medical Faculty, Medical University of Plovdiv, 6000 Plovdiv, BulgariaDepartment of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, University Eye Clinic, University Hospital, 4000 Plovdiv, BulgariaDepartment of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, University Eye Clinic, University Hospital, 4000 Plovdiv, BulgariaDepartment of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, University Eye Clinic, University Hospital, 4000 Plovdiv, BulgariaDepartment of General and Clinical Pathology, Faculty of Medicine, Medical University of Plovdiv, 4000 Plovdiv, BulgariaDepartment of Nursing Care, Faculty of Public Health, Medical University of Plovdiv, 4000 Plovdiv, BulgariaDepartment of Urology and General Medicine, Medical University of Plovdiv, 4000 Plovdiv, BulgariaJanus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical scrutiny. This comprehensive literature review embarks on an exploration of the multifaceted landscape of JAK inhibitors, providing insights into their safety profiles across diverse immune-mediated diseases. The introduction highlights the transformative influence of JAK inhibitors in the treatment of immune-mediated diseases. Historically, the therapeutic arsenal for these conditions included corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics. The advent of JAK inhibitors has revolutionized this landscape, although concerns about their safety persist. This review strives to comprehensively evaluate their safety, amalgamating knowledge from multiple studies and trials. The subsequent sections delve into the safety of specific JAK inhibitors in the context of rheumatoid arthritis, inflammatory bowel diseases, and dermatologic conditions and their associations with venous thromboembolism. The evolving understanding of TE risk, particularly the intricate relationship between these agents and immune-mediated diseases, is meticulously unravelled. The concluding remarks underscore the dynamic nature of TE risk assessment with regard to immune-mediated diseases involving JAK inhibitors. It underscores that risk assessment is multifactorial, influenced not only by the choice of JAK inhibitor but also by the nuances of the underlying immune-mediated disease and the unique patient characteristics. This review offers a holistic perspective on TE risks associated with JAK inhibitors and contributes to the ongoing dialogue regarding their safety in the realm of immune-mediated diseases.https://www.mdpi.com/2075-1729/13/12/2244JAK inhibitorsimmune-mediated diseasessafety profileadverse events |
| spellingShingle | Krasimir Kraev Mariela Gencheva Geneva-Popova Bozhidar Krasimirov Hristov Petar Angelov Uchikov Stanislava Dimitrova Belova-Popova Maria Ilieva Kraeva Yordanka Mincheva Basheva-Kraeva Nina Staneva Stoyanova Vesela Todorova Mitkova-Hristova Maria Stoyanova Koleva-Ivanova Daniela Ivova Taneva Atanas Slavchev Ivanov Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review Life JAK inhibitors immune-mediated diseases safety profile adverse events |
| title | Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review |
| title_full | Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review |
| title_fullStr | Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review |
| title_full_unstemmed | Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review |
| title_short | Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review |
| title_sort | examining the safety profile of janus kinase jak inhibitors in the management of immune mediated diseases a comprehensive review |
| topic | JAK inhibitors immune-mediated diseases safety profile adverse events |
| url | https://www.mdpi.com/2075-1729/13/12/2244 |
| work_keys_str_mv | AT krasimirkraev examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT marielagenchevagenevapopova examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT bozhidarkrasimirovhristov examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT petarangelovuchikov examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT stanislavadimitrovabelovapopova examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT mariailievakraeva examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT yordankaminchevabashevakraeva examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT ninastanevastoyanova examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT veselatodorovamitkovahristova examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT mariastoyanovakolevaivanova examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT danielaivovataneva examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview AT atanasslavchevivanov examiningthesafetyprofileofjanuskinasejakinhibitorsinthemanagementofimmunemediateddiseasesacomprehensivereview |